行情

CERC

CERC

Cerecor
NASDAQ

实时行情|Nasdaq Last Sale

4.000
+0.630
+18.69%
盘后: 4.000 0 0.00% 16:00 12/06 EST
开盘
3.440
昨收
3.370
最高
4.060
最低
3.440
成交量
11.49万
成交额
--
52周最高
7.65
52周最低
2.710
市值
1.76亿
市盈率(TTM)
-6.7170
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CERC 新闻

  • Cerecor To Acquire Aevi Genomic Medicine For $16.1M In An All-Stock Transaction
  • Benzinga.3天前
  • Cerecor to Acquire Aevi Genomic Medicine
  • GlobeNewswire.3天前
  • 趣头条Q3净营收14.07亿元 超市场预期
  • 新浪美股.5天前
  • 趣头条第三季度净营收14.07亿 高于市场预期
  • 新浪科技.5天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

CERC 简况

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.
展开

Webull提供Cerecor Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。